Besides the relatively short intervention duration, this seems to further reinforce our conclusion that SGLT-2 inhibitors have more meaningful clinical efficacy in improving cardiac remodeling in type 2 diabetes patients with HFrEF, rather than in those with diabetes alone. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.